- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02483598
Mechanistic Investigation Of Intestinal Cytochrome p450 3A4 Following Roux-en-Y Surgery And Its Effect on Plasma Concentrations of Buspirone
August 22, 2018 updated by: Kristine Steffen, North Dakota State University
This study is to compare intestinal Cytochrome P450 3A4 (CYP3A4) activity in 9-18 month post weight loss surgery Roux-en-Y Gastric Bypass (RYGB) versus control subjects who have not had a weight loss surgery and are of similar age, gender, body mass index as the gastric bypass group.
For this purpose, we will compare post-bariatric surgery patients with control subjects on alterations in systemic exposure of buspirone, a CYP3A4 substrate, when administered with grapefruit juice, a selective intestinal CYP3A4 inhibitor.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
12
Phase
- Phase 4
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 63 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or Female
- Age 18-65 (inclusive, at time of informed consent)
- No tobacco use in the past three months.
- Underwent Roux-en-Y Gastric Bypass weight loss surgery 9-18 months prior to study OR has not had a weight loss surgery but matches the gastric bypass patients on age, gender, and BMI.
- Ability to read, write and understand English.
- Expresses the ability/willingness to consume grapefruit juice.
Exclusion Criteria:
- Taking a medication that has a clinically significant interaction with buspirone or grapefruit juice or an interaction that may alter the study data.
- Hypersensitivity to buspirone or any excipient contained within the dosage forms or grapefruit juice.
- Inability to tolerate repeated blood draws.
- Any history of bipolar disorder or a psychotic disorder.
- Current major depressive disorder or current suicidality.
- Alcohol or substance dependence in the past year.
- Currently pregnant or lactating or unwillingness to use medically accepted contraception during study.
- Taking a medication which significantly alters gastrointesinal transit time.
- Medical conditon which may increase participant risk with buspirone or grapefruit juice.
- Self reported history of viral hepatits or HIV.
- Positive urine drug screen unless documented prescription of a non-interacting medication.
- Renal impairment as evidenced by an estimated glomerular filtration rate (eGFR) of less than or equal to 60 ml/min/1.73 m2 or other abnormality on a renal panel that the medical provider feels puts the participant at risk.
- Hepatic insufficiency as defined by any hepatic enzyme greater than 3x the upper limit of normal or other hepatic laboratory abnormalities at the discretion of the medical provider.
- Any contraindication to bioelectrical impedance analysis (BIA) such as pregnancy, the presence of a pacemaker or other implanted mechanical device.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Buspirone
Buspirone alone
|
The primary aim of this study is to compare the relative difference between the area-under-the-curve (AUC) of buspirone alone (buspirone) with the AUC of buspirone in the presence of grapefruit juice (buspirone + GFJ) in patients who underwent RYGB 9-18 months prior versus a control group of participants who have not undergone bariatric surgery.
Grapefruit juice will be given before and during buspirone administration to inhibit intestinal CYP3A4.
|
Active Comparator: Buspirone plus grapefruit juice
|
The primary aim of this study is to compare the relative difference between the area-under-the-curve (AUC) of buspirone alone (buspirone) with the AUC of buspirone in the presence of grapefruit juice (buspirone + GFJ) in patients who underwent RYGB 9-18 months prior versus a control group of participants who have not undergone bariatric surgery.
Grapefruit juice will be given before and during buspirone administration to inhibit intestinal CYP3A4.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area-under-the-curve
Time Frame: 9-18 months following RYGB
|
The primary aim of this study is to compare the relative difference between the area-under-the-curve (AUC) of buspirone alone (buspirone) with the AUC of buspirone in the presence of grapefruit juice (buspirone + GFJ) in patients who underwent RYGB 9-18 months prior versus a control group of participants who have not undergone bariatric surgery.
|
9-18 months following RYGB
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Composite of pharmacokinetic measures compared between buspirone and buspirone with grapefruit juice in participants who have undergone RYGB and nonsurgical control participants.
Time Frame: 9-18 months following RYGB
|
General pharmacokinetic comparisons (Cmax, Tmax, half-life, etc.) will be made between the two conditions.
|
9-18 months following RYGB
|
Compare GLP-2 levels between the buspirone and buspirone with grapefruit juice in participants who have undergone RYGB and nonsurgical control participants.
Time Frame: 9-18 months following RYGB
|
To compare GLP-2 levels between participants and drug conditions.
|
9-18 months following RYGB
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2015
Primary Completion (Actual)
June 1, 2018
Study Completion (Actual)
June 1, 2018
Study Registration Dates
First Submitted
June 22, 2015
First Submitted That Met QC Criteria
June 24, 2015
First Posted (Estimate)
June 29, 2015
Study Record Updates
Last Update Posted (Actual)
August 24, 2018
Last Update Submitted That Met QC Criteria
August 22, 2018
Last Verified
August 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- bus-000
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastric Bypass
-
Mayo ClinicCompletedRoux-en-Y Gastric Bypass | Gastric Bypass | Bariatric SurgeryUnited States
-
Washington University School of MedicineNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedRoux-en-Y Gastric Bypass | Bariatric Surgery | Vertical Sleeve Gastrectomy | Gastric Banding | Bypass, GastricUnited States
-
Hvidovre University HospitalUnknownGastric Bypass | Gastric BandingDenmark
-
State University of New York - Upstate Medical...TerminatedGastric Bypass StatusUnited States
-
Mayo ClinicNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)WithdrawnGastric Bypass Surgery
-
RSP Systems A/SCompleted
-
Rijnstate HospitalCompletedRoux-en-Y Gastric Bypass | Gastric Emptying | Bariatric SurgeryNetherlands
-
Wageningen UniversityRijnstate HospitalUnknownRoux-en-Y Gastric BypassNetherlands
-
North Dakota State UniversityNeuropsychiatric Research Institute, Fargo, North DakotaCompletedRoux en Y Gastric BypassUnited States
-
Medtronic - MITGCompleted
Clinical Trials on Buspirone
-
Johns Hopkins Bloomberg School of Public HealthJohns Hopkins University; Massachusetts General Hospital; National Institute... and other collaboratorsCompleted
-
Massachusetts General HospitalBrainCells Inc.CompletedMajor Depressive DisorderUnited States
-
Beijing Union Pharmaceutical Factory LtdR&G Pharma Studies Co.,Ltd.RecruitingGeneralized Anxiety DisorderChina
-
Spaulding Rehabilitation HospitalRecruitingSpinal Cord InjuriesUnited States
-
Par Pharmaceutical, Inc.Phoenix International Life Sciences, Inc.CompletedTo Determine Bioequivalence Under Fed ConditionsCanada
-
Par Pharmaceutical, Inc.Phoenix International Life Sciences, Inc.CompletedTo Determine Bioequivalence Under Fasting ConditionsCanada
-
Laikο General Hospital, AthensCompleted
-
University of OxfordCompleted
-
Nordic Life Science Pipeline Inc.United States Department of DefenseCompleted
-
Northwestern UniversityNational Alliance for Research on Schizophrenia and DepressionCompletedSchizophrenia | Schizoaffective DisorderUnited States